Indian Stocks For Domestic Demand When US Tariff Risks Return

US tariff risks on Indian exports are back in focus, and that pushes domestically driven stories into the spotlight. If a broad 12.5% US tariff hits a wide range of Indian exports, companies that rely mainly on India’s own consumers and businesses may look relatively insulated compared with export heavy peers. This article explains how that backdrop could matter for a portfolio and introduces 3 stocks from a Domestic Consumption-Focused Indian Companies screener that are more closely tied to India’s internal economy than to overseas demand.

Landmark Cars (NSEI:LANDMARK)

Overview: Landmark Cars is a large auto dealership group in India, selling passenger vehicles and accessories for brands such as Mercedes Benz, Honda, Renault, Jeep, Volkswagen, BYD and several others, while also offering financing, insurance and roadside assistance. The company runs a nationwide showroom and workshop network that supports customers through pre sales consultation and after sales service.

Operations: Landmark Cars generates about ₹48,962 million in revenue from car dealership activities in India.

Market Cap: ₹17.6b

Landmark Cars provides exposure to India’s car buying cycle, with all of its revenue coming from domestic dealership and after sales operations rather than exports that could be affected by potential US tariffs. Its OEM partners, including premium and luxury brands such as Mercedes Benz, Renault and Stellantis, are linking their India plans to new models and free trade agreements. Management states that these factors could expand the higher end market. At the same time, the company’s P/E multiple is well above the Specialty Retail average and earnings rely on thin net margins and external funding. Execution on new workshops and product launches therefore plays a significant role in its performance profile.

Landmark Cars’ premium brand mix and rich after sales income stream could be masking a very different earnings profile than its headline P/E suggests. It is worth reviewing the 2 key rewards and 2 important warning signs (1 is major!)

Radico Khaitan (NSEI:RADICO)

Overview: Radico Khaitan is a long established Indian spirits company that produces and sells whisky, brandy, rum, gin, vodka, liqueurs and country liquor, while also offering bottling services for other spirit manufacturers across India and select international markets.

Operations: Radico Khaitan generates about ₹60,504.3 million in revenue from manufacturing and trading liquor and alcohol.

Market Cap: ₹545.6b

Radico Khaitan provides pure exposure to India’s liquor consumption story at a time when export focused sectors face tariff headlines. Most of its business is tied to premium and luxury brands that target rising disposable incomes rather than overseas demand. Earnings and margins have been moving up alongside capacity additions and a richer product mix, and recent product refreshes such as the premium relaunch of After Dark Blue Grain Whisky illustrate how the portfolio is being pushed further upmarket. At the same time, a very high P/E multiple, reliance on a concentrated set of hero brands, and sensitivity to state level alcohol policies and input costs mean expectations are demanding and execution needs to stay tight.

Radico Khaitan’s premium push looks powerful, but the real story sits in how pricing, state policies and brand concentration interact over time, which is laid bare in the 2 rewards

Apollo Hospitals Enterprise (NSEI:APOLLOHOSP)

Overview: Apollo Hospitals Enterprise is a large Indian healthcare group that runs hospitals, pharmacies, clinics and diagnostic centers across the country. It is supported by its Apollo 24/7 digital platform for teleconsultations, online pharmacy and home diagnostics, along with specialized services in areas such as cardiac care, oncology, organ transplants and genomics.

Operations: Apollo Hospitals Enterprise generates about ₹127.5b from Healthcare Services, ₹108.1b from Digital Health & Pharmacy Distribution, ₹18.7b from Retail Health & Diagnostics and a small amount from Others.

Market Cap: ₹1,271.2b

Apollo Hospitals Enterprise provides exposure to India’s healthcare spending, with almost all revenue tied to domestic patients rather than exports that could be affected by potential US tariffs. The company combines a large hospital network, rising contribution from higher complexity specialties and a scaled digital platform with strong recent fundamentals, including earnings growth, expanding margins and high Return on Equity. At the same time, a rich valuation, meaningful use of external borrowing and competitive pressure in digital health and pharmacies mean there is little room for disappointment. The balance between quality, growth and these financial risks is where the main investment debate on Apollo lies.

Apollo Hospitals Enterprise looks like a quality and growth story, but the real twist is how its earnings, margins and borrowing sit together. Review the analysis report for Apollo Hospitals Enterprise to see what might be hiding in plain sight.

The three stocks here are just a starting point, and the full Domestic Consumption-Focused Indian Companies screener surfaced 32 more companies with equally compelling stories that tie closely to India’s internal economy, all brought together in the Domestic Consumption-Focused Indian Companies screener. Use Simply Wall St to identify and analyze the specific catalysts, financial traits and narratives that matter to you so you can focus on the highest conviction ideas in this theme.

Take Control of Your Investment Journey

If Apollo Hospitals Enterprise or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Markets can move quickly and the most attractive setups may not stay quiet for long. Consider reviewing these fresh stock lists while they may still be under the radar.

• Target dependable cash generators by reviewing a curated 473 dividend fortresses that aims to balance income potential with balance sheet strength before yields change.
• Spot under-the-radar growth stories by scanning the hand picked 500 high quality undiscovered gems before momentum builds and valuations move higher.
• Review potential infrastructure opportunities by checking the focused 34 power grid technology and infrastructure stocks while these grid and technology names may still be attracting limited attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com